Bionovo, Inc. (Nasdaq: BNVI) 93.8% HIGHER; today announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer.
In the trial, Bezielle showed an excellent safety and tolerability profile, and also showed promising indications of efficacy in a difficult-to-treat population. Click here for the full report.
WPT Enterprises, Inc.
advanced breast cancerMorning Movers 8/4: BNVI, LF, NPO, ANPI, LOOK, PRGX Higher; WPTE...StreetInsider.com News Articles Tue, 08/04/2009 - 08:15
After-Hours Movers 7/7: AMGN, RT, ALKS, SHLM Higher; NEXM, XNPT,...StreetInsider.com News Articles Tue, 07/07/2009 - 16:05
NexMed, Inc. (Nasdaq: NEXM) 64.1% LOWER; announced the mutual decision with Novartis (NYSE: NVS) to terminate the licensing agreement for NM100060, a topically-applied treatment for onychomycosis, commonly known as nail fungus. |
